Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

ORCHID

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID). (NCT04157335)

Recently completed/closed

ASKG315-101

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05509985)

Currently recruiting

IKS014-01 IKSUDA

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors (NCT05872295)

Currently recruiting

CLN-619-001

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05117476)

Currently recruiting

AMG176

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT02675452)

Recently completed/closed

HP518-CS-001 HINOVA

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients with Metastatic Castration-Resistant Prostate Cancer HP518-CS-001 (NCT05252364)

Recently completed/closed

PRT2527-02

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)

Currently recruiting

MK-6837

A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (NCT06460961)

Currently recruiting

KT-US-656-0601

A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma (NCT06079164)

Currently recruiting

AROATXN2

A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (NCT06672445)

Currently recruiting

INI-822-001

A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of INI-822 In Healthy Volunteers And Participants With Non-Alcoholic Steatohepatitis [NASH] Or Presumed NASH (NCT05945537)

Currently recruiting

BGB-C354-001

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (NCT06422520)

Currently recruiting

LOXO-IDH-20001

A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)

Recently completed/closed

Regeneron R2810-ONC-1787

A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB [REGN2810], ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA [CSCC] OR BASAL CELL CARCINOMA [BCC] (NCT03889912)

Currently recruiting

TAIHO 10058060

A Phase 1 study of TAS-116 (pimitespib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (NCT05245968)

Currently recruiting

80948543LYM1001

A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)

Currently recruiting

87801493LYM1001

A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs) (NCT06139406)

Currently recruiting

SNV1521

A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)

Currently recruiting

BGB-16673-101

A Phase 1, Open-Label, Dose Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein Degrader BGB-16673 in Patients with B Cell Malignancies (BGB-16673-101) (NCT05006716)

Currently recruiting

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma (NCT06478693)

Currently recruiting
2 3 4 5 6